Prospective, Single-arm, Phase II Study of Nab-paclitaxel Plus Carboplatin in Combination With Sintilimab for Neoadjuvant Therapy in Elderly, Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma.
Latest Information Update: 13 May 2024
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Sintilimab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 13 May 2024 New trial record